AZN

Key Takeaways

At $174.90 the market is paying about 32x company-wide operating income, which implies roughly 22% operating growth a year for five years. That is a demanding bar, but it is what a high-growth oncology franchise with a $80 billion 2030 revenue target invites. The fundamentals are running well below that implied rate today, yet the trajectory is real. Q1 2026 total revenue grew 13% to $15.3 billion (8% at constant currency), with oncology up 16% at constant currency to $6.8 billion and 14 regula

Institutional ownership

1,343 institutional managers reported holding AZN in 13F filings for the quarter ended 2026-03-31. Together they hold about 47% of the company; the top 10 hold 21%. 259 opened new positions that quarter. Held by Vanguard Group, FMR (Fidelity), Capital Group (American Funds), among others. On the short side, 1.3M shares were sold short as of the 2026-06-15 count, about 0.1% of shares outstanding (1 days of typical volume to cover).

Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.

Capital returns

AZN's share count grew 118.6% over the past five years. It pays a dividend, and has paid one every year in our records (11 and counting). Cash returned over the past three years: $20.49B in dividends.

Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.

Compare AZN

ABT vs AZNAZN vs BMYAZN vs GILDAZN vs JNJAZN vs LLYAZN vs MRK